"The Galleri test, made by American pharmaceutical firm Grail, can detect fragments of cancerous DNA that have broken off a tumour and are circulating in the blood. The trial followed 25,000 adults from the US and Canada over a year. Nearly one in a 100 of those tested had a positive result and in 62% of these cancer was later confirmed."
"When combined with breast, bowel and cervical screening it increased the number of cancers detected overall seven-fold. Crucially, three quarters of cancers detected were for those which have no screening programme such as ovarian, liver, stomach bladder and pancreas. The blood test correctly identified the origin of the cancer in 9 out of 10 cases. These impressive results suggest the blood test could eventually have a major role to play in diagnosing cancer earlier."
"Scientists not involved in the research say more evidence is needed to show whether the blood test reduces deaths from cancer. The topline results are to be released at the European Society for Medical Oncology congress in Berlin, but the full details have yet to be published in a peer reviewed journal. Much will depend on the results of a three-year trial involving 140,000 NHS patients in England, which will be published next year."
The Galleri blood test detects fragments of cancerous DNA circulating in the blood and can screen for more than 50 cancer types. A trial of 25,000 adults in the US and Canada found nearly 1% had a positive result, with cancer later confirmed in 62% of positives, while the test correctly ruled out cancer in over 99% of negative results. More than half of cancers detected were at an early stage, and three quarters were cancers that currently lack screening programmes. The test located the cancer origin in nine of ten cases. Full peer-reviewed results are pending, and larger NHS trials will assess impact on mortality.
Read at www.bbc.com
Unable to calculate read time
Collection
[
|
...
]